3 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 4 Phase 2, 4 Phase 3, 2 Phase 1, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 3, Completed 1 |
| Phase 3 | 4 | Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow molgramostim: new trials by email Literature Review of molgramostim trials Research Report on molgramostim
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Molgramostim - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Recruiting | Savara Inc. | 5 | 2025-10-22 | 2026-02-19 |
| Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei Pseudovax, Molgramostim, Tislelizumab - Pseudomyxoma Peritonei | Early Phase 1 | Recruiting | Oslo University Hospital | 10 | 2025-10-13 | 2026-01-14 |
| PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy - Malignant Ascites | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 40 | 2022-09-01 | 2022-08-15 |
| Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Molgramostim, Placebo, Molgramostim Open-label - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Active not recruiting | Savara Inc. | 164 | 2021-05-19 | 2026-11-03 |
| Effect of rhGM-CSF on the Healing of Venous Leg Ulcers rhGM-CSF + hydrogel, Placebo hydrogel, Standard care - Venous Leg Ulcer | Phase 2 | Unknown | Reponex Pharmaceuticals A/S | 6 | 2021-03-11 | 2022-11-17 |
| Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Molgramostim - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Terminated | Savara Inc. | 60 | 2018-04-16 | 2024-07-03 |
| Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis Molgramostim, Placebo, PARI eFlow nebulizer system - Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Completed | Savara Inc. | 139 | 2016-03-21 | 2023-04-12 |
| Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Molgramostim, Placebo - Pulmonary Alveolar Proteinosis, Bronchiectasis | Phase 1 | Completed | Savara Inc. | 42 | 2015-05-01 | 2017-02-23 |
| Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients CSF470 vaccine, BCG, Molgramostim, interferon alpha 2b - Cutaneous Melanoma | Phase 2 / Phase 3 | Unknown | Laboratorio Pablo Cassara S.R.L. | 108 | 2009-04-01 | 2015-09-02 |
| Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years ARA-C, Idarubicin, Leucomax - Acute Myeloblastic Leukaemia | Phase 4 | Completed | PETHEMA Foundation | 100 | 1998-10-01 | 2010-01-05 |
Pulmonary Alveolar Proteinosis, Acquired (4) · Pulmonary Alveolar Proteinosis (2) · Bronchiectasis (1) · Cystic Fibrosis (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1) · Pseudomyxoma Peritonei (1) · Respiratory Distress Syndrome (1) · Varicose Ulcer (1)
Savara Inc. (5) · Laboratorio Pablo Cassara S.R.L. (1) · Oslo University Hospital (1) · PETHEMA Foundation (1) · Reponex Pharmaceuticals A/S (1) · Second Affiliated Hospital of Soochow University (1)
Germany (4) · United Kingdom (4) · Denmark (3) · France (3) · Greece (3) · Italy (3) · Netherlands (3) · Spain (3) · Turkey (Türkiye) (3) · Australia (2) · Israel (2) · Japan (2) · Portugal (2) · Russia (2) · South Korea (2)
Bruce Trapnell, MD (1) · Cliff Morgan, MD (1) · Ewa A Burian, MD (1) · Francesco Bonella, Prof. (1) · Johnston Steward, MD (1) · Matthias Griese, MD, (1)
PMID 24117042, PMID 28620382, PMID 29774030, PMID 40834301, PMID 40973220
2015 (1), 2017 (1)